Sciclone Pharmaceut (SCLN) 10.02 $SCLN SciClone To

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2016 at 11:01 PM

Sciclone Pharmaceut (SCLN) 10.02 $SCLN

SciClone To Present At Two Investor Conferences In September 2016
PR Newswire - Thu Sep 01, 3:05PM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will present a corporate overview and business update at two investor conferences in September 2016.
SCLN: 10.02 (+0.01)

SciClone Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended June 30, 2016.
SCLN: 10.02 (+0.01)

Sciclone Pharmaceuticals Has Returned 70.9% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Fri Jun 10, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 70.93% as of today's recent price of $13.63.
SCLN: 10.02 (+0.01)

Shares of SCLN Up 74.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:11AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 74.17% as of today's recent price of $13.89.
SCLN: 10.02 (+0.01)

Sciclone Pharmaceuticals Shares Up 62.9% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Thu May 26, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 62.88% as of today's recent price of $12.99.
SCLN: 10.02 (+0.01)

AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 45.80 (-0.54), SCMP: 11.10 (unch), SCLN: 10.02 (+0.01), BIOD: 0.42 (unch)

Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 64.4% (SCLN)
Comtex SmarTrend(R) - Wed May 11, 12:42PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 6 months, Sciclone Pharmaceuticals has returned 64.39% as of today's recent price of $13.11.
SCLN: 10.02 (+0.01)

SciClone Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2016.
SCLN: 10.02 (+0.01)

SciClone Pharmaceuticals To Report First Quarter 2016 Financial Results On May 10, 2016
PR Newswire - Mon Apr 25, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2016 on Tuesday, May 10, 2016. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET (5:30 am PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
SCLN: 10.02 (+0.01)

Shares of SCLN Up 62.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 19, 12:15AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 62.51% as of today's recent price of $12.96.
SCLN: 10.02 (+0.01)

Sciclone Pharmaceuticals Shares Up 55.3% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Mon Apr 11, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 55.30% as of today's recent price of $12.39.
SCLN: 10.02 (+0.01)

Shares of SCLN Up 37.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 01, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 37.62% as of today's recent price of $10.98.
SCLN: 10.02 (+0.01)

Look for Shares of Sciclone Pharmaceuticals to Potentially Pullback after Yesterday's 13.34% Rise
Comtex SmarTrend(R) - Thu Mar 31, 3:35PM CDT
Sciclone Pharmaceuticals (NASDAQ:SCLN) traded in a range yesterday that spanned from a low of $10.35 to a high of $10.99. Yesterday, the shares gained 13.3%, which took the trading range above the 3-day high of $9.99 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SCLN: 10.02 (+0.01)

WebMD Health Set to Join the S&P MidCap 400; SciClone Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Wed Mar 30, 5:24PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, April 1:
WBMD: 52.41 (+0.36), TMO: 151.18 (+0.23), SUNE: 0.34 (unch), SCLN: 10.02 (+0.01), MHFI: 107.92 (+1.16), AFFX: 14.01 (+0.02)

SciClone To Present At Needham Healthcare Conference On April 13, 2016
PR Newswire - Wed Mar 30, 5:00AM CDT
FOSTER CITY, Calif., March 30, 2016 /PRNewswire/-- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 15th Annual Needham Healthcare Conference at 8:00 am ET on Wednesday, April 13, 2016, at the Westin Grand Central Hotel in New York City.
SCLN: 10.02 (+0.01)

SciClone Announces Final Resolution With The Securities And Exchange Commission And The Department Of Justice
PR Newswire - Thu Feb 04, 4:02PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) (the "Company"

today announced it has entered into a settlement agreement with the United States Securities and Exchange Commission (SEC) fully resolving the SEC's investigation into possible violations of the Foreign Corrupt Practices Act (FCPA). Under the terms of the settlement agreement, SciClone has agreed to pay a total of $12.8 million, including disgorgement, pre-judgment interest and a penalty. This payment is in line with the charges the Company previously recorded and disclosed in its Form 10-Q filed with the SEC on August 10, 2015. As part of the agreement, the Company neither admits nor denies it engaged in any wrongdoing. The Department of Justice (DOJ) has also completed its related investigation and has declined to pursue any action.
SCLN: 10.02 (+0.01)

SciClone To Present At BIO CEO & Investor Conference On February 9, 2016
PR Newswire - Wed Jan 27, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 18th Annual BIO CEO & Investor Conference at 8:30 am ET on Tuesday, February 9, 2016, at the Waldorf Astoria Hotel in New York City.
SCLN: 10.02 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pyxus Starts Exchange Offer for 8.50% Notes, 2027

Pyxus Restructures Via Exchange Offer Pites, it's time for Pyxus International to show its hand. The global agricultural player has rolled up its sleeves, kicking off an exchange offer for its 8.50% notes maturing in 2027. With $148.3 million hanging in the balance, this move is their shot at managing debt and keeping things steady—like a farmer making sure the...

Nevada Organic Phosphate Cancels Share Consolidation Plan

Unexpected Turn for Nevada Organic Phosphate In an abrupt twist that surprised some investors, Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) (FSE: ZV8), the Canadian trailblazer in organic phosphate mining, called off its proposed share consolidation. Dropping the plan wasn't just a stroke of luck; it came after hearing the grumblings of shareholders concerned...

Inner City Visions Celebrates Two Decades of Impact

Alfred Lomas' Transformation Fuels Lasting Change Once upon a time, Alfred Lomas was known as a brawler in the rough patches of South L.A., running with gangs and entangled in violence. But the story flipped, and instead of leaning into chaos, Lomas leaned into hope. That personal turnaround isn't just a headline—it's the crux behind Inner City Visions (ICV), the...

Elong Kicks Off Central Asia Strategy with Almaty Launch

Elong's Strategic Move into Central Asia When a company like Elong Hotel Technology decides to plant its flag in Central Asia, it’s more than just another overseas venture. This brand launch in Almaty is a bold statement—a signal that they're here to shake things up in a region ripe for development but lacking in hotel chains. With only about 20% penetration for local...

PMET's High-Stakes Call on Shaakichiuwaanaan Update

Inside PMET Resources' Critical Investor Briefing Now, this is the kind of investor chatter that cuts to the core of PMET's game plan. We're talking the big guns coming out with PMET Resources (TSX: PMET) as they gear up for what's poised to be a tell-all investor teleconference about their Shaakichiuwaanaan Project. Yep, mark your calendars because on Tuesday, November...

GFL Stays Public: Board Sees Growth Beyond Buyout

GFL Environmental Says 'No Thanks' to Takeover Bids Wall Street loves a juicy M&A story, but GFL Environmental decided it’s not playing ball. In a world where companies seem to flip like properties on a hot market, GFL has boldly told prospective buyers to buzz off. They want to stay public, continue carving their path without the trappings of private equity overlords....

HI-CHEW® Holiday Mix Debuts Three Seasonal Flavors

HI-CHEW® Puts Holiday Cheer on the Shelves In the candy aisle, it’s never just about sugar—it’s about the flavor journey. This year, HI-CHEW® is pulling off a sweet, festive coup with its first-ever Holiday Mix, making sure that your taste buds aren't left out in the cold. But hey, I’m a seasoned investor talking about candy here, not stocks. Unwrapping the New...

First Graphene Taps Deeper into US Defense Market

Graphene Making Waves in Defense Fresh off the press, folks. First Graphene Limited is struttin' onto the US defense scene with a repeat order for its PureGRAPH®—a big deal in the realm of electrically conductive inks. The tally comes to around A$35,000 in an order from a longtime American customer. We're talking about inks that print circuits, sensors, and more,...

Quantinuum & RIKEN Propel Japan's Quantum Leap Forward

Quantum Computing: Japan's Bold New Frontier Quantum computing's buzz is getting louder, and the big players like Quantinuum and RIKEN ain't sitting on their hands. They've rolled up their sleeves to ramp up Japan's quantum-AI supercomputing game with the recent beef-up of Quantinuum's Reimei to its H2 system, putting Japan at the cutting edge of hybrid computing. The...

Solar Cooking Revolution: InventHelp's Latest Innovation

A Bright Idea Shines with Solar Cooking Some days, you stumble across an idea that just seems destined to shake things up, and COOK SOL SOLAR POWER COOKER might just be one of those spark plugs ready to ignite the world of outdoor cooking. Invented by a plucky thinker from Florence, South Carolina, this little gadget isn't just about frying up eggs on a camping trip. Nah,...